Bruyer A, Maes K, Herviou L, Kassambara A, Seckinger A, Cartron G, Rème T, Robert N, Requirand G, Boireau S, Müller-Tidow C, Veyrune JL, Vincent L, Bouhya S, Goldschmidt H, Vanderkerken K, Hose D, Klein B, De Bruyne E, Moreaux J. DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells. British Journal of Cancer. 2018. Download the PDF
Summary of the Study
This study investigates the combined epigenetic targeting of DNA methyltransferases (DNMTi) and histone deacetylases (HDACi) in multiple myeloma (MM), aiming to define predictive markers of response and therapeutic potential.
Key findings
Developed a Combo Score based on gene expression to predict MM cell sensitivity to DNMTi/HDACi therapy
High Combo Score identified a patient group with:
- Worse overall survival
- Increased sensitivity to epigenetic therapy
Combo treatment induced:
- Repression of IRF4 and MYC
- Gene expression reprogramming toward a mature bone marrow plasma cell profile
- Apoptosis and reduced proliferation in high-risk MM
In this study, Alboukadel Kassambara contributed to the bioinformatic analyses, supporting the development and validation of the Combo Score and its biological interpretation in the context of epigenetic reprogramming in multiple myeloma.
Citation
Publication: In British Journal of Cancer
Date: March 2, 2018
Type: Journal Article
PDF: Download the PDF
Scientific Contributions
Here are more scientific abstracts authored or co-authored by Alboukadel Kassambara. These contributions span computational biology, bioinformatics, biostatistics, machine learning, and multi-omics, with a focus on immuno-oncology and translational research.
